Physician profile
Natalie E Cusano
NPI 1568620425
$74,537.31
in general payments reported to CMS, 2019-2025
8 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $20.66 · 2021: $12K · 2022: $10K · 2023: $10K · 2024: $8,674 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $2,830 · Travel and Lodging: $1,091 · Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,438.19 |
| Consulting Fee | $2,830.00 |
| Travel and Lodging | $1,091.08 |
| Food and Beverage | $606.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $39,346.40 | 2019-2024 | Strensiq |
| Shire North American Group INC | $28,605.02 | 2019 | |
| Ascendis Pharma Endocrinology INC | $4,759.89 | 2023-2025 | Yorvipath |
| Radius Health, INC. | $1,620.00 | 2019 | |
| Amgen INC. | $142.71 | 2019-2024 | Evenity, Prolia |
| Novo Nordisk INC | $42.63 | 2021-2024 | Wegovy |
| Lilly USA, LLC | $20.66 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Cusano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.